We discovered that ruxolitinib at clinically relevant free drug concentrations synergized with the multiple sclerosis drug MMF to kill a wide variety of solid tumor cell types, particularly breast and brain tumor cells, including those cells expressing mutated active RAS or ERBB1 proteins, or lacking the tumor suppressor PTEN. The gene discussed is EGFR; the disease is brain neoplasm.